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Long Overall Survival After Dendritic Cell Vaccination in
Metastatic Uveal Melanoma Patients
KALIJN F. BOL, HANNEKE W. MENSINK, ERIK H.J.G. AARNTZEN, GERTY SCHREIBELT, JAN E.E. KEUNEN,
PIERRE G. COULIE, ANNELIES DE KLEIN, CORNELIS J.A. PUNT, DION PARIDAENS, CARL G. FIGDOR, AND
I. JOLANDA M. DE VRIES PURPOSE: To assess the safety and efficacy of dendritic
cell vaccination in metastatic uveal melanoma.
 DESIGN: Interventional case series.
 METHODS: We analyzed 14 patients with metastatic
uveal melanoma treated with dendritic cell vaccination.
Patients with metastatic uveal melanoma received at
least 3 vaccinations with autologous dendritic cells,
professional antigen-presenting cells loaded with mela-
noma antigens gp100 and tyrosinase. The main outcome
measures were safety, immunologic response, and over-
all survival.
 RESULTS: Tumor-specific immune responses were
induced with dendritic cell vaccination in 4 (29%)
of 14 patients. Dendritic cell-vaccinated patients showed
a median overall survival with metastatic disease of
19.2 months, relatively long compared with that reported
in the literature. No severe treatment-related toxicities
(common toxicity criteria grade 3 or 4) were observed.
 CONCLUSIONS: Dendritic cell vaccination is feasible
and safe in metastatic uveal melanoma. Dendritic cell-
based immunotherapy is potent to enhance the host’s
antitumor immunity against uveal melanoma in approxi-
mately one third of patients. Compared with other pro-
spective studies with similar inclusion criteria, dendritic
cell vaccination may be associated with longer than
average overall survival in patients with metastatic uveal
melanoma. (Am J Ophthalmol 2014;158:939–947.
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U
VEALMELANOMA IS THEMOSTCOMMONPRIMARY
intraocular malignancy in adults with an annual
incidence of 4 to 10 per 1 million in the white
population, although representing only 3% of all mela-
noma cases.1,2 Uveal melanoma arises from melanocytes
residing in the uveal tract of the eye that have migrated
out of the neural crest. Approximately 90% of uveal
melanoma arise in the choroid, 6% in the ciliary body,
and 4% in the iris.3 In up to 50% of the patients with pri-
mary uveal melanoma, metastatic disease ultimately de-
velops, which occurs by hematogenous dissemination; the
median time from initial diagnosis of uveal melanoma until
detection of metastatic disease ranges from 2 to 5 years.4–7
Currently, there is no effective systemic treatment for
metastasis to improve overall survival,8 resulting inevitably
in tumor-related death when metastasis occurs, with the
minor exceptions of a small proportion of patients who
have successful curative surgery of metastasis or patients
with spontaneous regression of metastatic disease.
Prognostic factors to identify patients with primary uveal
melanoma at risk for metastatic disease include clinical
(tumor location, tumor size, age), histologic (cell type,
vascular pattern, mitotic count, extraocular extension), and
genetic (chromosomal aberrations, expression profiling,
gene mutations) parameters, partially included in the Amer-
ican Joint Committee on Cancer classification of uveal mel-
anoma.9–11 Over the past few decades, treatment of the
primary tumor has changed drastically because several
forms of radiotherapy have replaced enucleation as the
preferred treatment of the primary tumor, depending on
size and location of the tumor and patient preference.
However, despite the improvements in diagnosis and the
development of eye-conserving treatments, none of these
treatment methods prevents the development of metastases.
The relative 5-year survival rates have not increased over the
past decades, fluctuating at approximately 70%to80%.4,12–14
Only up to 2% of patients have detectable metastasis
when their primary uveal melanoma is diagnosed15; most
patients have a long disease-free interval before metastasis
becomes clinically evident.4 In uveal melanoma, liver me-
tastases are seen most frequently (90% to 95%), and it is939ELSEVIER INC. ALL RIGHTS RESERVED.
often the sole site of metastatic disease. Other common
sites of metastases, mostly in the presence of liver metasta-
ses, are lungs (25%), bone (15%), skin (10%), and lymph
nodes (10%); in contrast to cutaneous melanoma, uveal
melanoma infrequently metastasizes to the brain.16 After
metastasis develops, overall survival mainly is independent
of previously mentioned prognostic factors if one is identi-
fying patients with primary uveal melanoma at risk for met-
astatic disease. Presence of symptomatic disease, metastatic
extensiveness, and metastatic-free interval may correlate
with survival time.17 Nevertheless, median survival is
short, typically less than 9 months, with a poor 1-year sur-
vival rate (10% to 40%).7,17–19 The small group of patients
in whom metastases are confined to extrahepatic locations
have a significantly longer median survival, approximately
19 to 28 months.20,21
Several locoregional treatment options can be considered
in selected patients with metastasis confined to the liver,
including surgery, isolated hepatic perfusion, or radiofre-
quency ablation. Although prolonged survival has been re-
ported after surgical resection of liver metastasis,20 this may
be the result in part of selection bias. To date, treatment op-
tions formetastatic uveal melanoma are limited, and compel-
ling evidence that any systemic therapy, including
chemotherapy, improves overall survival is lacking.6 Disease
stabilization is described in several patients receiving ipilimu-
mab, which recently has shown survival benefit in metastatic
cutaneousmelanomapatients.22However, data are basedona
limited number of patients.23,24 Therefore, effective therapies
resulting in meaningful clinical benefit are required urgently,
and immunotherapy may be a promising treatment method.
Immune-based therapies aim to induce antitumor immu-
nity. Despite uveal melanoma developing in the immune-
privileged environment of the eye, immune cells have been
found within uveal melanoma, including dendritic cells and
T cells.25–27 Dendritic cells are antigen-presenting cells
with the unique capacity to activate naı¨ve antigen-specific
T cells, and hence are suitable for inducing immunologic anti-
tumor responses (Figure 1). Dendritic cell-based immuno-
therapy has shown promising results in cutaneous melanoma
patients.28 Although uveal and cutaneous melanoma are
different biologically, cutaneous melanoma and uveal mela-
noma sharemanyantigenic features, including tumorantigens,
providing a rationale for the application of dendritic cell-based
therapies in uveal melanoma. The tumor antigens used in our
dendritic cell vaccination studies for metastatic melanoma
patients, gp100 and tyrosinase, are both expressed in most
human uveal melanoma tumor cells,29,30 and thus constitute
an appropriate target for immunotherapy in uveal melanoma.
Our research group has performed several prospective
dendritic cell vaccination studies in patients with mela-
noma, of which most consisted of patients with cutaneous
melanoma.We here present data on the subset of metastatic
uvealmelanoma patients whowere enrolled in these studies.940 AMERICAN JOURNAL OFMETHODS
THE STUDIES WERE APPROVED BY THE DUTCH CENTRALE
Commissie Mensgebonden Onderzoek (Central Com-
mittee on Research Involving Human Subjects), and writ-
ten informed consent to participate in research
was obtained from all patients. The trials were registered
at ClinicalTrials.gov (identifiers NCT00940004, NCT
01690377, NCT01530698, and NCT00243529).
 PATIENT CHARACTERISTICS: We analyzed a cohort of
14 patients with metastatic uveal melanoma who were
enrolled in our prospective dendritic cell vaccination
studies between October 2002 and May 2011. Patients
were required to have at least 1 measurable target lesion.
Additional inclusion criteria were melanoma expressing
the melanoma-associated antigens gp100 (compulsory)
and tyrosinase (noncompulsory), HLA-A*02:01 pheno-
type (protocols I, III, IV, V, and VI), known HLA-
DRB*01:04 status (protocol IV), and World Health
Organization performance status 0 or 1. Patients with
serious concomitant disease or a history of second malig-
nancy were excluded.
 TREATMENT SCHEDULE: All patients were vaccinated
with autologous dendritic cells loaded with tumor-
associated antigens of gp100 and tyrosinase according to
a schedule of 3 biweekly vaccinations. One to 2 weeks after
the last vaccination, a skin test was performed; see the
treatment schedule in Figure 1. In absence of disease pro-
gression, patients received a maximum of 2 maintenance
cycles at 6-month intervals. Variations in protocols
included the type of dendritic cells, route of administration,
method of antigen loading, and pretreatment with anti-
CD25 antibody, described in the Supplemental Table
(available at AJO.com). Stable disease was defined accord-
ing to Response Evaluation Criteria in Solid Tumors with a
minimal duration of 4 months. Adverse events were graded
according to the National Cancer Institute Common Ter-
minology Criteria for Adverse Events version 3.0.
 DENDRITIC CELL VACCINE: Monocytes, enriched from
leukapheresis products, were cultured in the presence of
interleukin-4 (500 U/mL) granulocyte-macrophage
colony-stimulating factor (800 U/mL; both Cellgenix, Frei-
burg, Germany) and control antigen keyhole limpet hemo-
cyanin (10 mg/mL; Calbiochem, Darmstadt, Germany).
Dendritic cells were matured with autologous monocyte-
conditioned medium (30%, vol/vol) supplemented with
prostaglandin E2 (10 mg/mL; Pharmacia & Upjohn, Puurs,
Belgium) and 10 ng/mL tumor necrosis factor-a (Cellge-
nix) for 48 hours as described previously.31 All adminis-
tered dendritic cell vaccines met the release criteria
previously described.32 In the Supplemental MethodsNOVEMBER 2014OPHTHALMOLOGY
FIGURE 1. Diagram showing dendritic cell (DC) vaccination rational and treatment schedule. DCs are antigen-presenting cells with
the unique capacity to activate naı¨ve antigen-specific T cells, and by this means are very suitable to induce immunologic antitumor
responses. (Left) DCs cultured from monocytes can be loaded with tumor antigen ex vivo and administered to cancer patients via
different routes, after culture in the presence of maturation stimuli. (Middle) Within the lymph node, DCs present antigens to
T cells to initiate an immune response. (Right) The activated tumor antigen-specific T cells proliferate and migrate out of the lymph
node toward the site of the antigen, the tumor site, to effectuate T-cell killing of tumor cells. Patients were vaccinated with autologous
DCs loadedwith tumor antigens (gp100 and tyrosinase), obtained by leukapheresis, according to a schedule of 3 biweekly vaccinations.
One to 2 weeks after the last vaccination, a skin test was performed to analyze the induction of immunologic responses. Computed
tomography (CT) scans were performed before vaccination and every 3 months thereafter. CD4 [ CD4D T-helper cell; CD8 [
CD8D cytotoxic T cell; DTH[ delayed type hypersensitivity skin test; i.d.[ intradermal; i.n.[ intranodal; i.v.[ intravenous.(available at AJO.com), a detailed description on dendritic
cell culture is provided.
 ANALYSES OF IMMUNOLOGIC RESPONSES: To assess the
immune response against control and tumor peptides
generated in vaccinated patients, peripheral blood was
drawn and delayed-type hypersensitivity challenges were
performed.28,33 In the Supplemental Methods (available
at AJO.com), a detailed description of immunomonitoring
tests is provided.
 FLUORESCENT IN SITU HYBRIDIZATION ANALYSIS:
Fresh tumor material from enucleated eyes containing
uveal melanoma were cultured routinely for karyotyping
and were used directly for fluorescent in situ hybridization
(FISH) analysis of chromosome 3 as previously described.34
Dual-color FISH was performed with the following probes:
Pa3.5 (centromere 3), RP11-64F6 (3q25), and RP11-
1059N10 (5q12). Chromosome 5 is rarely involved in ge-
netic changes in uveal melanoma and was used as a control
for aneuploidy, truncation, and cutting artifacts. The con-
centration for centromeric probe was 5 ng per slide,VOL. 158, NO. 5 IMMUNOTHERAPY IN Uwhereas for the bacterial artificial chromosome probes,
50 to 75 ng per slide was used. After hybridization
and washing, the slides were counterstained with 49,
6-diamidino-2-phenylindole and mounted in antifade solu-
tion (Dabco-Vectashield 1:1; Vector Laboratories, Burlin-
game, California, USA). Signals were counted in 300
interphase nuclei. Scoring for deletion (>20% of the nuclei
with 1 signal) or amplification (>10% of the nuclei with 3
signals or more) was adapted from the available literature.35
Using FISH analysis, we subdivided the variation in chro-
mosome 3 into the following categories: monosomy 3 (loss
of 1 copy), disomy 3 (normal copy numbers [2 copies]), and
hyperdiploidy (gain of 1 copy).
 STATISTICALANALYSIS: Overall survival was calculated
from the date of leukapheresis to death. Patients who did
not die during the follow-up period were censored at the
time of last follow-up. The Kaplan-Meier method was
used to obtain estimates of median survival times and to
generate survival curves. IBM SPSS Statistics (SPSS
version 20.0) software (SPSS, Inc., Chicago, Illinois,
USA) was used for statistical analysis.941VEAL MELANOMA
TABLE 1. Characteristics of Dendritic Cell-Vaccinated Patients With Metastatic Uveal Melanoma
Patient Gender
Age
(y)
LTD
(mm) Chromosome 3
Treatment
of Primary
No. of
Metastases Site of Metastatic Disease
LDH
(U/L)
LDM
(mm)
Prior Treatment
for Metastases
I-C14 M 54 14 Disomy E 1 Liver 312 33 No
III-B7 M 54 13 Monosomy E 2 Liver 277 16 No
III-B8 M 40 13 Monosomy E 3 Liver 1289 Diffuse No
IV-A4 M 51 13 Monosomy E >5 Liver 417 41 No
IV-A10 F 54 n.a. Monosomy No >5 Liver, lung 432 17 No
IV-B11 M 65 n.a. n.t. RT >10 Liver, lymph node, lung 640 182 C1
IV-D3 F 42 n.a. Monosomy RT/L >10 Liver, lymph node, lung, pancreas 344 19 S, C1
V-A3 M 52 n.a. n.t. Ru >5 Liver, bone 517 56 RFA, P/T
VI-B6 M 53 15 Disomy E, RT >5 Liver, lung, bone, soft tissue 434 40 S
VI-DE3 M 62 23 Hyperdiploidy E, RT >5 Liver, lung 360 17 No
VI-DE4 M 35 16 n.t. E >5 Liver, lymph node, soft tissue 320 47 No
VIII-A1 F 49 12 Monosomy E >5 Liver 424 16 No
VIII-A4 F 46 12 Disomy Ru/Th >5 Skin, large intestine, soft tissue 440 25 S
VIII-DE2 F 70 12 Monosomy E >10 Liver, lymph node, lung, adrenal gland 447 53 C1
C1¼ chemotherapy (DTIC/dacarbazine); E¼ enucleation; F¼ female; L¼ laser; LDH¼ lactate dehydrogenase (upper limit of normal, 450 U/
L); LDM¼ diameter of the largest measurable metastasis; LTD¼ largest tumor diameter of primary uveal melanoma;M¼male; n.a.¼ not avail-
able; n.t. ¼ not tested; P/T ¼ pazopanib/topotecan; RFA ¼ radiofrequency ablation; RT ¼ radiotherapy; Ru ¼ ruthenium; S ¼ surgery;
Th ¼ thermotherapy.RESULTS
 PATIENTCHARACTERISTICS: Fourteen uveal melanoma
patients with metastatic disease were enrolled in dendritic
cell vaccination studies. Patient characteristics are shown
in Table 1. The mean age was 52 years; 9 patients were
men and 5 were women. One patient had metastases
confined to extrahepatic locations. All other patients had
liver metastases, of which the liver was the sole site of
metastasis in 5 patients. Six patients had received prior
treatment for their metastatic disease, mostly consisting
of surgery or dacarbazine (chemotherapy). Lactate dehy-
drogenase, (if elevated, a negative prognostic factor in met-
astatic uveal melanoma), was elevated at baseline in 3 of 14
patients. Median time between diagnosis of the primary tu-
mor and metastatic disease was 20.4 months. Four patients
had synchronous metastasis at presentation (Table 2).
All tumors were confirmed histopathologically as uveal
melanoma. Histopathologic examination results of the pri-
mary tumor were available in 9 patients who were treated
with enucleation. Based on cell type, 8 primary tumors
were classified as epithelioid or mixed and 1 as spindle.
The median largest tumor diameter of the primary tumor
was 13 mm. One tumor was located in the ciliary body
(VI-DE3) and 11 were located in the choroid (2 unknown
primary location in the ciliary body or choroid). In 12 of 14
patients, metastatic disease was confirmed by histopatho-
logic analysis. All uveal melanoma tumor cells tested, 6 pri-
mary tumors and 8 metastases, showed positive results for
gp100 expression. Additionally, 11 of 12 uveal melanoma
tumor cells tested also expressed tyrosinase.942 AMERICAN JOURNAL OF CYTOGENETIC RESULTS: Uveal melanomas of 11 pa-
tients were analyzed for chromosomal changes by using cyto-
genetic and FISH analyses and were classified for gain and
loss in chromosome 3 (Table 1). Analyses were performed
on primary tumors in 5 patients, on metastases in 4 patients,
and on both in 2 patients. Not enough tumor material was
available to analyze the remaining 3 patients. Clonal chro-
mosomal abnormalitieswere present in8 of 11 tumors tested.
Seven tumors showed monosomy 3, 3 patients showed
disomy, and 1 patient had a tumor showing hyperdiploidy
of chromosome3.Nodiscrepancieswere seen in the patients
where both the primary tumor and a metastasis were tested.
 IMMUNOLOGIC RESPONSES: To test the capacity of the
patients in this study to generate an immune response
with vaccination, dendritic cells were loaded with a control
antigen. Peripheral blood mononuclear cells collected after
each vaccination were analyzed for the presence of control
antigen-specific T cells. Almost all patients (12 of 14)
showed a cellular response to control antigen in the first cy-
cle. In 7 of 13 patients tested, control antigen-specific IgG
antibodies were detected after vaccination (Table 3).
These results indicate that the vaccine induced de novo
immune responses. To determine the presence of tumor
antigen-specific CD4þ and CD8þ T cells, tetramer ana-
lyses for 1 tyrosinase and 2 gp100 epitopes were performed
after 3 vaccinations. In peripheral blood, tetramer-positive
CD4þ T cells, indicative of tumor recognition by T-helper
cells, could be seen in 1 of 2 HLA-DRB*01:04-positive pa-
tients tested, which were also detectable in the blood
before dendritic cell vaccination.NOVEMBER 2014OPHTHALMOLOGY
TABLE 2. Treatment and Clinical Outcomes of Dendritic Cell-Vaccinated Metastatic Uveal Melanoma Patients
Patient
Time to
Metastases (mo)
No. of
Vaccinations
PFS
(mo)
Later Treatment for
Metastases
OS from Primary
Diagnosis (mo)
OS from
Apheresis (mo)
Best Clinical
Response
I-C14 44 3 6 S (32) 130a 84a SD
III-B7 0 3 2 C1 10 7 PD
III-B8 8 3 2 C1 11 3 PD
IV-A4 10 3 5 C1 32 19 SD
IV-A10 2 6 14 No 55 52 SD
IV-B11 103 3 5 No 145 9 SD
IV-D3 1 3 6 C2, S 53 26 SD
V-A3 27 3 2 Ipi 55 4 PD
VI-B6 68 3 4 RT 85 13 SD
VI-DE3 32 3 5 C1, Ipi, AKTi 71 38 SD
VI-DE4 90 3 5 C1, C2/WKi, P/Ifos, Ipi 120 27 SD
VIII-A1 0 3 2 C1 12 10 PD
VIII-A4 97 9 28 PKCi 136a 32a SD
VIII-DE2 20 9 22 RT 52 26 SD
AKTi¼ protein kinase B inhibitor; C1¼ chemotherapy (DTIC/dacarbazine); C2¼ chemotherapy (temozolomide); Ipi¼ ipilimumab; OS¼ over-
all survival; PD ¼ progressive disease; PFS ¼ progression-free survival; P/ifos ¼ pazopanib/ifosfomide; PKCi ¼ protein kinase C inhibitor;
RT ¼ radiotherapy; S ¼ surgery; SD ¼ stable disease; Wki ¼ Wee 1 kinase inhibitor.
aOngoing/not dead.
TABLE 3. Immunologic Responses to Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients
Patient
Control
Antigen-Specific
T-Cell Response (Blood)
Control Antigen-Specific
Antibody Response
(Blood)
Tumor Antigen-Specific
CD8þ T-Cell Response
(Skin Test)
Tumor Antigen-Specific
CD8þ T-Cell Response
(Blood)
Tumor Antigen-Specific
CD4þ T-Cell Response
(Blood)
I-C14 þ    n.t.
III-B7 þ    n.t.
III-B8 þ n.t. n.t.  n.t.
IV-A4 þ þ þ  þa
IV-A10 þ þ   
IV-B11 þ þ þ  n.a.b
IV-D3 þ þ   n.a.b
V-A3 þ    n.t.
VI-B6 þ    n.t.
VI-DE3 þ þ  þ n.t.
VI-DE4  þ  þ n.t.
VIII-A1 þ  n.a. n.a.c n.t.
VIII-A4 þ þ n.a. n.a.c n.t.
VIII-DE2 þ    n.t.
n.a. ¼ not applicable; n.t. ¼ not tested; þ ¼ response present;  ¼ response absent.
aTumor antigen-specific CD4þ T-cell response also was detectable in the blood before dendritic cell vaccination.
bHLA-DRB*01:04–negative patients.
cHLA-A*02:01–negative patients.In 3 patients (protocol VI), blood mononuclear cells
were restimulated in vitro over 2 weeks with the 3 anti-
genic peptides, before screening all microcultures for the
presence of CD8þ tetramer-positive cells. This procedure
allowed estimation of the frequencies of tumor antigen-
specific CD8þ T cells in blood that proliferate in vitro
in response to tumor antigen. Two patients showed aVOL. 158, NO. 5 IMMUNOTHERAPY IN Usignificant increase (>_5-fold) of the frequency of gp100-
specific CD8þ T cells.
Antigen-specific CD8þ T cells were detected in
delayed-type hypersensitivity skin tests in 2 of 11 HLA-
A*02:01-positive patients (Figure 2; Table 3). In patient
IV-B11, functionality of the antigen-specific CD8þ
T cells was tested, and they proved to be fully functional943VEAL MELANOMA
FIGURE 2. Tumor-specific T cells in skin test after dendritic
cell vaccination in a metastatic uveal melanoma patient. To
assess the immune response against tumor peptides generated
in vaccinated patients, delayed-type hypersensitivity challenges
were performed with mature dendritic cells loaded with gp100,
tyrosinase, or both. The ability of skin test infiltrating lympho-
cytes to recognize vaccine-specific antigens was measured with
tetrameric-major histocompatibility complex (TM) complexes
by flow cytometry. (Top left) Skin test infiltrating lymphocytes
double-positive for CD8 and a specific tetrameric-major histo-
compatibility complex, tumor antigen-recognizing cytotoxic
T cells, are shown in the upper right quadrant. (Top right) An-
alyses of patient IV-A4 show skin test infiltrating lymphocytes
recognizing 1 of the gp100 epitopes tested. (Bottom left and Bot-
tom right) No skin test infiltrating lymphocytes recognizing
gp100:280 or tyrosinase are found in this patient.
FIGURE 3. Kaplan-Meier estimate for overall survival after
dendritic cell vaccination in metastatic uveal melanoma pa-
tients. Kaplan-Meier estimate for overall survival from leuka-
pheresis to date of death or censored at date of last follow-up.
Dendritic cell vaccinated patients showed long overall survival
with metastatic uveal melanoma; the median overall survival
was 19.2 months.and to produce high levels of interleukin-2 and interferon-
g on antigen-specific stimulation.
 CLINICAL OUTCOME: All patients received at least 3
vaccinations (1 cycle), and 1 patient did not have a skin
test because of rapid progressive disease. Ten patients
showed stable disease at the first evaluation point, 3 months
after start of vaccination, but 7 patients progressed before a
second cycle was started after 6 months according to proto-
col. One patient received a second cycle of vaccinations,
and 2 patients received all 3 vaccination cycles and had sta-
ble disease up to 28 months. Seven (50%) patients survived
more than 2 years after start of dendritic cell vaccination
for metastatic uveal melanoma. Thus far, 12 patients
have died of melanoma-related disease and 2 patients are
still alive with metastases. Figure 3 shows the Kaplan-
Meier curve for overall survival. Our patients were
substaged according to the American Joint Committee
on Cancer tumor-node-metastasis staging system for mela-
noma of the eye based on the diameter of the largest metas-944 AMERICAN JOURNAL OFtasis. Six patients hadM1a substage (diameter of the largest
metastasis of 3.0 cm or less), 6 patients had M1b substage
(diameter of the largest metastasis between 3.1 and
8.0 cm), and 2 patients had M1c substage (diameter of
largest metastasis more than 8.1 cm). Our patients showed
a median overall survival of 29 months for M1a,
22.5 months for M1b, and 6 months for M1c.
 SIDEEFFECTS: No severe toxicity (grade 3 or 4) occurred.
The vaccine-related side effects observed in the vaccinated
patients were grade 1 fatigue (5 patients), flu-like symptoms
(8 patients), and erythema at the intradermal injection site
(6 patients).
DISCUSSION
THE INTRINSIC RESISTANCE OF UVEALMELANOMATO CON-
ventional systemic therapies has made the treatment of
metastatic uveal melanoma a tough challenge. The devel-
opment of uveal melanoma at an immune-privileged site,
the eye, made it questionable if immunotherapy would be
a suitable treatment method. The lack of proper immune
surveillance in the eye can lead to characteristics that
make tumor cells more susceptible for recognition by the
immune system when cells disseminate systemically, for
example, high expression of tumor-specific antigens, asNOVEMBER 2014OPHTHALMOLOGY
well as less susceptible, for example, resistance to inter-
feron-g–induced upregulation of major histocompatibility
complex class II molecules.36–38 At present, accumulating
evidence shows that uveal melanoma tumor cells can be
lysed by CD8þ T cells in vitro39 and by T cells adoptively
transferred in a mouse model,40 indicating the susceptibil-
ity of uveal melanoma for immunotherapy.
In our study, we vaccinated metastatic uveal melanoma
patients with autologous, mature dendritic cells to induce
or strengthen a tumor-specific immune response. First, we
showed that dendritic cell vaccination in metastatic uveal
melanoma is feasible and safe, as shown in more than 200
patients with cutaneous melanoma. Second, the control
antigen-specific T-cell proliferation indicated that the vac-
cine effectively induced de novo immune responses in all
patients. Tumor-specific CD8þ T cells were detected in
29% of patients in peripheral blood or in antigen-
challenged skin sites. Our previous findings in metastatic
melanoma patients, of which most had cutaneous mela-
noma, showed a similar immunologic response rate
(32%) and demonstrated that the presence of tumor-
specific T cells after dendritic cell vaccination correlates
with clinical outcome.28 The cohort is too small to confirm
these data in metastatic uveal melanoma patients.
Obviously, our study has several limitations. First, this
study consists of a small cohort, mainly because of rarity
of the tumor and selection on HLA-A*02:01 phenotype
in most protocols (approximately 50% of the white popula-
tion).41 The latter was necessary because the selected pep-
tides only bind HLA-A*02:01. We do not expect that this
has influenced our results, because HLA-A*02:01 pheno-
type has shown no correlation with survival.42 Other fac-
tors were more likely to be of influence on overall
survival, for example, excluding patients with World
Health Organization performance status of 2 or more.
However, patients were not excluded based on anatomic
site of metastasis, number of metastases, or metastatic-
free interval, all known to be prognostic factors in metasta-
tic uveal melanoma.17
The primary end point of the dendritic cell vaccination
studies was safety and feasibility; however, the data on
overall survival appeared interesting. The median overall
survival of the vaccinated patients was 19.2 months, calcu-
lated from the day of leukapheresis instead of from diag-
nosis of metastasis, as is done in unselected case series.
Overall survival from date of diagnosis of metastatic disease
in our dendritic cell vaccinated patients was 30.3 months.
According to the American Joint Committee on Cancer
Staging Manual, median overall survival is 17 months for
M1a, 9 months for M1b, and 4.5 months for M1c.43 Our pa-
tients showed a median overall survival of 29 months for
M1a, 22.5 months forM1b, and 6months forM1c. No large
difference in overall survival was seen in patients who
received prior therapy for metastatic disease to treat-
ment-naı¨ve patients. Comparing our results on survival
with other published series, the observed median overallVOL. 158, NO. 5 IMMUNOTHERAPY IN Usurvival of 19.2 months in dendritic cell-vaccinated pa-
tients not only exceeded the overall survival as reported
in studies using systemic treatment (range, 5.2 to
15.3 months), but also the overall survival in almost all
studies in more selected metastatic uveal melanoma pa-
tients treated with local therapies of the liver (range, 5.2
to 24 months), such as surgical resection of liver metastasis,
hepatic artery chemoembolization, and hepatic artery infu-
sion chemotherapy.17 These invasive therapies excluded
patients with extrahepatic metastasis and high World
Health Organization performance status, that is, have
more strict inclusion criteria, and consequently included
patients with more favorable prognostic factors. Further
comparison with a cohort of patients with a similar propor-
tion of pretreated patients (12 of 20 patients) and selection
criteria, treated with treosulfan and gemcitabine, showed a
similar median overall survival (19.2 vs 17 months).44
Although our results do not allow definite conclusions
about clinical outcome, the immunologic responses, previ-
ously shown to correlate with clinical outcome,28 and the
observed long overall survival in our cohort of metastatic
uveal melanoma patients seem promising. Additionally,
theminimal toxicity associated with dendritic cell vaccina-
tion compares favorably with other treatment methods.
As to metastatic patients, the high tumor burden may
hamper the induction of effective immune responses,
creating a suppressive tumor microenvironment by the
secretion of suppressive cytokines and attraction of regula-
tory T cells.45 Robust immunologic responses on dendritic
cell vaccination are induced more frequently in patients
with no evidence of disease (72%) (manuscript in prepara-
tion) compared with patients with macroscopic tumor
burden (32%).28 On the basis of the association of
tumor-specific T cells and improved clinical outcome,
this suggests that dendritic cell-based vaccination may
have a more pronounced role in an adjuvant setting and
should be initiated at an early stage after tumor resection.
Patients with primary uveal melanoma usually have no
detectable metastatic disease at the time of diagnosis, and
most patients have a lengthy disease-free interval before
metastasis become evident. Therefore, after treatment of
the primary tumor, in the presence of only minimal residual
disease and with little immune suppression, there is suffi-
cient time to develop an effective immune response with
adjuvant dendritic cell vaccination. Furthermore, patients
with a high risk for relapse could be selected based on
monosomy 3 status. The presence of monosomy 3 in the
primary tumor is accepted widely as the most simple and
reliable prognostic parameter, identified in approximately
50% of patients with primary uveal melanoma.46 Long-
term studies have shown a 3-year survival rate of 40% if
monosomy 3 is present, whereas tumors with normal chro-
mosome 3 status rarely give rise to metastatic disease and
have a 90% 3-year survival rate.47
To date, no adjuvant therapy has shown survival benefit
in uveal melanoma,48,49 and because immunologic945VEAL MELANOMA
responses are seen more frequently in patients before
clinically detectable metastasis develop, dendritic cell
vaccination may be a good candidate. We currently are
investigating this strategy in a randomized study. In
conclusion, we show that dendritic cell vaccination is946 AMERICAN JOURNAL OFfeasible and safe in metastatic uveal melanoma. Our data
suggest the potential of dendritic cell-based immuno-
therapy to enhance the host’s antitumor immunity and
that it may be associated with longer than average overall
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SUPPLEMENTAL METHODS. DENDRITIC CELL
VACCINATION AND MONITORING OF
IMMUNOLOGIC RESPONSES
 DENDRITIC CELL VACCINE: Monocytes were enriched
from leukapheresis products by counterflow centrifugation
using an Elutra-cell separator (Gambro BCT, Inc, Lake-
wood, Colorado, USA) and single-use, functionally
sealed disposable Elutra sets, according to the manufac-
turer. Monocytes were cultured in the presence of inter-
leukin (IL)-4 (500 U/mL) granulocyte-macrophage
colony-stimulating factor (800 U/mL; both Cellgenix,
Freiburg, Germany) and control antigen keyhole limpet
hemocyanin (10 mg/mL; Calbiochem, Darmstadt,
Germany). Dendritic cells were matured with autologous
monocyte-conditioned medium (30%, v/v) supple-
mented with prostaglandin E2 (10 mg/mL; Pharmacia &
Upjohn, Puurs, Belgium) and 10 ng/mL tumor necrosis
factor-a (Cellgenix, Freiburg, Germany) for 48 hours as
described previously.1 Plasmacytoid dendritic cells and
myeloid dendritic cells were isolated directly from
leukapheresis products using the fully closed immuno-
magnetic CliniMACS isolation system (Miltenyi Biotec,
Bergisch-Gladbach, Germany). Good manufacturing
practice-grade magnetic bead-coupled BDCA4 (plas-
macytoid dendritic cells) or BDCA1 (myeloid dendritic
cells) antibodies were used, following the manufac-
turer’s guidelines. Plasmacytoid and myeloid dendritic
cells were cultured overnight at a concentration of
106 cells/mL in X-VIVO-15 (Cambrex, Verviers,
Belgium) containing 2% pooled human serum (Sanquin,
Nijmegen, The Netherlands), supplemented with 10 ng/
mL recombinant human IL-3 (plasmacytoid dendritic
cells) or 800 U/mL granulocyte-macrophage colony-
stimulating factor (both Cellgenix) and 10 mg/mL con-
trol antigen (Calbiochem; myeloid dendritic cells). The
plasmacytoid dendritic cells were activated subsequently
for 6 hours by addition of FSME-IMMUN (1:10 v/v;
Baxter AG).2
Dendritic cells were pulsed with the human leukocyte
antigen (HLA) class I gp100-derived peptides gp100:154–
162, gp100:280–288, and the tyrosinase-derived peptide
tyrosinase:369–377. In one protocol, dendritic cells from
HLA-DRB*01:04–positive patients also were pulsed with
HLA-DRB*01:04–binding peptides of both gp100 and
tyrosinase (gp100:44–59 and tyro:448–462 analog).3 In
protocols IV, V, and VIII, mature dendritic cells were elec-
troporated with mRNA encoding gp100 or tyrosinase as
described previously,4 and cells were resuspended in
0.1 mL for injection.
All administered dendritic cell vaccines met the
release criteria described previously:5 mature phenotype
with low expression of CD14, high expression of major947.e1 AMERICAN JOURNAL OFhistocompatibility complex (MHC) class I, MHC class II,
CD83, and CD86 and expression of gp100 and tyrosinase
for mRNA-electroporated cells.
 FLOW CYTOMETRY: Flow cytometry was used to charac-
terize the phenotype of the ex vivo-generated dendritic
cells and immune cell subpopulations in the peripheral
blood. Flow cytometry measures multiple cell surface pro-
teins simultaneously after staining the cells with fluores-
cently labeled antibodies specific for a certain antigen.
The following monoclonal antibodies or appropriate
isotype controls were used: anti–HLA ABC (W6/32),
anti–HLA DR/DP (Q5/13), anti–HLA DR, anti-CD80
(all BD Biosciences, San Jose, CA, USA), anti-CD14,
anti-CD83 (both Beckman Coulter), anti-CD86 (BD Phar-
mingen, San Jose, CA, USA), and anti-CCR7 (kind gift of
Martin Lipp, Max Planck Institute, Berlin, Germany). For
intracellular staining, NKI/beteb (immunoglobulin [Ig]
G2b; purified antibody) against gp100 and T311 (IgG2a;
Cell Marque Corp, Rocklin, CA, USA) against tyrosinase
were used. Flow cytometry was carried out with FACSCa-
libur flow cytometer equipped with CellQuest software (BD
Biosciences, San Jose, CA, USA).
 CONTROL ANTIGEN-SPECIFIC PROLIFERATION: CD4þ
T-cell responses against the control antigen were
measured using a 3H-thymidine incorporation prolifera-
tion assay with peripheral blood mononuclear cells of
the patients before and after vaccination. Briefly, periph-
eral blood mononuclear cells were isolated from heparin-
ized blood by Ficoll-Paque density centrifugation,
stimulated with control antigen (4 mg/2 3 105 peripheral
blood mononuclear cells) in X-VIVO with 2% human
serum. After 3 days, cells were pulsed with 3H-thymidine
for 8 hours, and incorporation was measured with a
b-counter. Experiments were carried out in triplicate;
nonspecific proliferation on stimulation with ovalbumin
was used as control.
 CONTROLANTIGEN-SPECIFICANTIBODYPRODUCTION:
Antibodies against control antigen were measured in the
serum of vaccinated patients using enzyme-linked immu-
nosorbent assay (available at: http://www.klhanalysis.
com). Briefly, microtiter plates were coated with control
antigen, and different concentrations of patient serum
were allowed to bind. After washing, patient antibodies
were detected with mouse anti-human IgG, IgA, or IgM an-
tibodies labeled with horseradish peroxidase (Invitrogen,
San Diego, California, USA); 3,30–5,5-tetramethyl benzi-
dine was used as a substrate. An isotype-specific calibration
curve for the control antigen response was included in each
plate; the detection limit was determined at more than
20 mg/L.NOVEMBER 2014OPHTHALMOLOGY
 ANALYSES OF SKIN TEST INFILTRATING LYMPHOCYTES
FOR TUMOR RECOGNITION: To assess the immune
response against tumor peptides generated in vaccinated pa-
tients, delayed-type hypersensitivity challenges were
performed with mature dendritic cells loaded with gp100,
tyrosinase, or both. We have shown that the presence of
skin test-infiltrated, tumor-specific T cells correlated with
clinical outcome.6,7 Skin tests were performed within 1 to
2 weeks after each vaccination cycle. Briefly, dendritic
cells pulsed with gp100, tyrosinase, or both epitopes or
electroporated with mRNA encoding either gp100,
tyrosinase, or both were injected intradermally in the skin
of the back of the patient at different sites. After 48 hours,
the maximum diameter of induration was measured by
palpation, and punch biopsy samples (6 mm) were
obtained. Half of the biopsy was cryopreserved by snap
freezing and the other part was cut manually and cultured
for 2 to 4 weeks in RPMI-1640 containing 7% human serum
and IL-2 (100 U/mL). Every 7 days, half of the medium was
replaced by fresh medium containing human serum and IL-
2. After 2 to 4 weeks of culturing, skin test-infiltrating lym-
phocytes of HLA-A*02:01-positive patients were stained
with tetrameric-MHC complexes as described previously.7
Each tetramer was validated by staining against a cytotoxic
lymphocyte cell line specific for HLA-A*02:01 in associa-
tion with the peptide of interest. The ability of skin
test-infiltrating lymphocytes to recognize vaccine-specific
antigens and produce cytokines was determined by the pro-
duction of cytokines and cytotoxic activity of skin test infil-
trating lymphocytes in response to T2 pulsed with the
indicated peptides or BLM (a melanoma cell line expressing
HLA-A*02:01 but no endogenous expression of gp100 and
tyrosinase), transfected with control antigen G250, with
gp100 or tyrosinase, or with an allogeneic HLA-
A*02:01-positive, gp100-positive, and tyrosinase-positive
tumor cell line (MEL624).6 In 2 HLA-A*02:01–negative
patients, antigen recognition was determined using autolo-
gous EBV-transformed B cells as described previously.8
 MIXED LYMPHOCYTE–PEPTIDE CULTURES: Blood fre-
quencies of antivaccine CD8þT cells were estimated using
mixed lymphocyte–peptide cultures in protocol VI as
described previously.2,9 Briefly, peripheral blood
mononuclear cells isolated before and after 1 cycle of
plasmacytoid dendritic cell vaccinations were thawed and
divided in 3 groups incubated for 1 hour at room
temperature in Iscove’s medium (Life Technologies,
Carlsbad, California, USA) with 1% human serum and
2 mM of the peptides tyrosinase:369–377 (YMDGTMS
QV), wild-type gp100:154–168 (KTWGQYWQV), or
wild-type gp100:280–288 (YLEPGPVVTA). These pulsed
cells then were washed, pooled, and distributed at 2 3
105 cells/0.2 mL in round-bottom microwells in Iscove’s
with 10% human serum, L-arginine (116 mg/L), L-aspara-
gine (36mg/L), L-glutamine (216mg/L), 1-methyl-L-trypto-
phan (100 mM), IL-2 (20 U/mL), and IL-7 (10 ng/mL). OnVOL. 158, NO. 5 IMMUNOTHERAPY IN Uday 7, 50% of the medium was replaced by fresh medium
containing IL-2 and peptides at 4 mM. Tetramer labeling
was performed on day 14 as described previously.9 Anti-
gp100:154–168 T-cell clones were derived that represented
either the spontaneous anti-gp100 T cells present before
vaccination or the plasmacytoid dendritic cell-induced
anti-gp100 T cells present after vaccination. Tetramer-
positiveCD8þT cells were sorted at 1 cell/well and restimu-
lated weekly with irradiated HLA-A*02þ EBV-transformed
B cells pulsed with the gp100:154–168 peptide at 2 mM, and
irradiated allogeneic peripheral blood mononuclear cells as
feeder cells, in medium supplemented with IL-2 and IL-7.
 TETRAMER STAINING: To determine the presence of
tumor-associated antigen-specific T cells, skin test-
infiltrating lymphocyte cultures and peripheral blood mono-
nuclear cells were reanalyzed and stained with tetrameric–
MHC complexes containing the MHC class I epitopes
gp100:154–168, gp100:280–288, or tyrosinase:369–377
(Sanquin) or MHC class II epitopes gp100:44–59 and tyrosi-
nase:448–462 (provided by W.W. Kwok, Benaroya Research
Institute, Seattle, Washington, USA), as described previ-
ously.3 In addition, in 2 patients, peripheral blood mononu-
clear cells were restimulated for 8 days with DR4-binding
gp100 or tyrosinase peptides and were stained with tetrameric
MHC complexes containing MHC-II epitopes gp100:44–59
and tyrosinase:448–462. Tetrameric MHC complexes recog-
nizing the human immunodeficiency virus were used as
correction for background binding. Tetramer positivity was
defined as at least 2-fold increase in the double-positive pop-
ulation.
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ypox virus. J Immunol 2003;171(9):4898–4904.SUPPLEMENTAL TABLE. Dendritic Cell Vaccination Protocols Used in Metastatic Uveal Melanoma Patients
Protocol No. of Patients Type of DC Method of Antigen Loading Route of Administration Anti-CD25
I1 1 moDC Class I mod i.v./i.d. No
III-B2 2 moDC Class I wt i.d. Yes
IV-A3 2 moDC Class I wt þ II i.n. No
IV-B3 1 moDC Class I wt i.n. No
IV-D4 1 moDC mRNA i.n. No
V-A4 1 moDC mRNA i.v./i.d. No
VI-Ba 1 myDC myDC Class I wt i.n. No
VI-DE5 2 pDC pDC Class I wt i.n. No
VIIIa 3 moDC mRNA i.v./i.d. No
Class I mod ¼ HLA class I-restricted modified gp100-derived peptides 154–162 Q/A and 280–288 A/V and HLA class I-restricted
tyrosinase-derived peptide 369–377; Class I wt ¼ HLA class I-restricted wt gp100-derived peptides 154–162 and 280–288 and HLA class I-
restricted tyrosinase-derived peptide 369–377; Class II¼ HLA class II-restricted gp100-derived peptide 44–59 and tyrosinase-derived peptide
448–462 analog; DC¼ dendritic cell; i.d.¼ intradermal; i.n.¼ intranodal; i.v.¼ intravenous; mod ¼modified; moDC¼monocyte-derived den-
dritic cell; mRNA ¼messenger RNA (encoding full-length gp100 and tyrosinase protein); myDC ¼myeloid dendritic cell; pDC ¼ plasmacytoid
dendritic cell; wt ¼ wild type.
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